Cytokinetics
Clinical trials sponsored by Cytokinetics, explained in plain language.
Biopharmaceutical company focused on muscle biology and cardiac muscle diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New heart failure pill shows promise in early trial Results expected Sep 2026 (estimated) May already have reported ↗
- New heart failure drug aims to cut hospitalizations and deaths Results expected Sep 2027 (estimated) May already have reported ↗
-
New heart failure drug aims to cut hospitalizations and deaths
Disease control Recruiting nowThis study tests an investigational drug called omecamtiv mecarbil in 1,800 adults with severe heart failure and a very weak heart pump. The goal is to see if it can lower the risk of heart failure worsening, hospitalization, need for a heart pump or transplant, or death. Partici…
Phase 3 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Aug 30, 2026 00:00 UTC
-
New heart failure pill shows promise in early trial
Disease control Recruiting nowThis study tests a new drug called CK-4021586 (ulacamten) in 60 adults with a type of heart failure where the heart pumps normally but is stiff (HFpEF). Participants take the drug or a placebo for 12 weeks to see if it is safe and how it affects heart function. The goal is to fin…
Phase 2 • Sponsor: Cytokinetics • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC